Zantac

Judge Overseeing Zantac Case Declines to Recuse Himself Despite Wife’s Connection to Law Firm

by

Miami, FL – A federal judge in Miami has ruled he will not recuse himself from overseeing a class-action lawsuit involving the heartburn medication Zantac, despite concerns over potential conflicts of interest due to his wife’s association with a law firm involved in the case. The controversy centers on U.S. District Judge Robin Rosenberg, whose wife is a partner at Reed Smith, a firm representing several companies named in lawsuits over the alleged cancer risks of ranitidine, the active ingredient in Zantac. Despite this connection, Judge Rosenberg has declared that his wife’s professional engagements and … Read more

Recent Developments in Zantac Litigation: Key Updates for Affected Consumers

by

Washington — Thousands of lawsuits have been filed against the manufacturers of Zantac and its generic forms, alleging that the popular heartburn medication may cause cancer. The legal battles represent a significant chapter in pharmaceutical litigation, underscoring ongoing concerns regarding drug safety and consumer protection. The controversy began after the U.S. Food and Drug Administration (FDA) warned in 2019 that Zantac (ranitidine) might contain a probable human carcinogen called N-nitrosodimethylamine (NDMA). Following these findings, the FDA requested the removal of all ranitidine products from the market in April 2020, leading to widespread recall and discontinuation … Read more

Delaware’s Latest Court Decision on Zantac: A New Haven for Mass Tort Litigations?

by

Wilmington, Del. — A recent legal decision in Delaware has sparked debate over its potential to attract a larger number of mass tort litigations, positioning the state as a burgeoning hub for these complex legal battles. This comes after a federal judge upheld a significant verdict related to the heartburn medication Zantac, triggering discussions in legal circles about the implications for future mass tort cases in the jurisdiction. Delaware, long recognized for its corporate-friendly laws and Chancery Court system, might now see an uptick in cases involving large groups of plaintiffs alleging harm from pharmaceuticals, … Read more

Delaware Braces for Wave of Mass Tort Cases Following Crucial Expert Testimony Ruling in Zantac Litigation

by

Wilmington, DE — Delaware could soon witness a significant uptick in mass tort litigation due to a recent pivotal decision involving the heartburn medication Zantac. The decision, which allowed expert testimony linking the drug to cancer, stands to set a legal precedent impacting numerous pending cases and potentially drawing more to the state’s courts. The ruling originated from lawsuits alleging that ranitidine, the active ingredient in Zantac, produces high levels of the carcinogen N-nitrosodimethylamine (NDMA) when ingested. Plaintiffs argue that this has led to various cancers among users, sparking widespread concern and subsequent legal action. … Read more